SpringWorks Therapeutics Inc. [NASDAQ: SWTX] slipped around -12.47 points on Friday, while shares priced at $18.36 at the close of the session, down -40.45%. The company report on May 26, 2022 that SpringWorks Therapeutics Highlights Nirogacestat Clinical Data at the 2022 ASCO Annual Meeting.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
– Initial Data to be Presented from GSK-Sponsored Phase 1/2 Study Evaluating Nirogacestat in Combination with Low-Dose BLENREP in Patients with Relapsed or Refractory Multiple Myeloma -.
– Long-Term Follow-up Data from NCI-Sponsored Phase 2 Study of Nirogacestat in Patients with Progressing Desmoid Tumors Also to be Presented -.
SpringWorks Therapeutics Inc. stock is now -70.38% down from its year-to-date (YTD) trading value. SWTX Stock saw the intraday high of $20.34 and lowest of $13.60 per share. The company’s 52-week high price is 89.75, which means current price is +35.00% above from all time high which was touched on 01/03/22.
Compared to the average trading volume of 599.72K shares, SWTX reached a trading volume of 15839130 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about SpringWorks Therapeutics Inc. [SWTX]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for SWTX shares is $94.75 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on SWTX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
H.C. Wainwright have made an estimate for SpringWorks Therapeutics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 19, 2021. While these analysts kept the previous recommendation, H.C. Wainwright raised their target price from $58 to $73. The new note on the price target was released on October 29, 2020, representing the official price target for SpringWorks Therapeutics Inc. stock. Previously, the target price had yet another raise to $48, while Barclays analysts kept a Overweight rating on SWTX stock. On March 19, 2020, analysts increased their price target for SWTX shares from 40 to 60.
The Average True Range (ATR) for SpringWorks Therapeutics Inc. is set at 4.53 The Price to Book ratio for the last quarter was 2.38, with the Price to Cash per share for the same quarter was set at 4.20.
How has SWTX stock performed recently?
SpringWorks Therapeutics Inc. [SWTX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -50.63. With this latest performance, SWTX shares dropped by -58.48% in over the last four-week period, additionally sinking by -73.19% over the last 6 months – not to mention a drop of -77.48% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for SWTX stock in for the last two-week period is set at 21.78, with the RSI for the last a single of trading hit 16.49, and the three-weeks RSI is set at 25.98 for SpringWorks Therapeutics Inc. [SWTX]. The present Moving Average for the last 50 days of trading for this stock 47.67, while it was recorded at 30.71 for the last single week of trading, and 60.07 for the last 200 days.
SpringWorks Therapeutics Inc. [SWTX]: Deeper insight into the fundamentals
Return on Equity for this stock declined to -35.51, with Return on Assets sitting at -33.81.
SpringWorks Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 15.30 and a Current Ratio set at 15.30.
Insider trade positions for SpringWorks Therapeutics Inc. [SWTX]
There are presently around $916 million, or 98.38% of SWTX stock, in the hands of institutional investors. The top three institutional holders of SWTX stocks are: FMR LLC with ownership of 6,046,209, which is approximately 53.211% of the company’s market cap and around 4.00% of the total institutional ownership; ORBIMED ADVISORS LLC, holding 6,028,307 shares of the stock with an approximate value of $110.68 million in SWTX stocks shares; and BAIN CAPITAL LIFE SCIENCES INVESTORS, LLC, currently with $88.7 million in SWTX stock with ownership of nearly 0% of the company’s market capitalization.
Positions in SpringWorks Therapeutics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 69 institutional holders increased their position in SpringWorks Therapeutics Inc. [NASDAQ:SWTX] by around 5,762,743 shares. Additionally, 69 investors decreased positions by around 2,031,396 shares, while 23 investors held positions by with 42,101,418 shares. The mentioned changes placed institutional holdings at 49,895,557 shares, according to the latest SEC report filing. SWTX stock had 15 new institutional investments in for a total of 551,065 shares, while 22 institutional investors sold positions of 608,940 shares during the same period.